Posted by Michael Wonder on 07 Jan 2025
GSK’s B7-H3 targeted antibody drug conjugate, GSK’227, receives US FDA breakthrough therapy designation in late-line relapsed or refractory osteosarcoma
7 January 2025 - Regulatory designation based on promising early data in this rare bone cancer.
GSK announced today that the US FDA has granted breakthrough therapy designation for GSK5764227, its B7-H3 targeted antibody drug conjugate being evaluated for the treatment of adult patients with relapsed or refractory osteosarcoma who have progressed on at least two prior lines of therapy.
